How to Verify Section 361 Compliance for Allografts

To verify Section 361 compliance for human tissue allografts, practices must audit the manufacturer's active FDA Form 3356 registration, inspect lot-specific donor eligibility records, and confirm that processing preserves structural characteristics without synthetic additives. Because registration alone does not signify FDA approval, procurement teams must look past marketing claims to independently substantiate minimal manipulation and homologous use. This clinical audit checklist details the specific documentation your practice needs to verify compliance and prevent regulatory exposure.

Understanding the Regulatory Divide: Section 361 vs. Section 351

When sourcing regenerative biologics such as amniotic membranes, Wharton's Jelly, or cord blood products, practice managers encounter two distinct regulatory pathways under the Public Health Service (PHS) Act: Section 361 and Section 351.

Products regulated solely under Section 361 and Title 21 of the Code of Federal Regulations (CFR) Part 1271 are subject to regulations designed to prevent the introduction, transmission, and spread of communicable diseases. These products do not require an Investigational New Drug (IND) application or a Biologics License Application (BLA) to be marketed.

Conversely, if a tissue allograft fails to meet even one of the statutory criteria laid out in 21 CFR 1271.10(a), it defaults to regulation under Section 351 as a drug, device, or biological product. Marketing or administering an unapproved Section 351 product without an active IND or BLA exposes a medical practice to regulatory enforcement. Therefore, knowing how to verify section 361 compliance for human tissue allografts is a foundational risk-management competency for any clinic offering regenerative medicine.

The Four Statutory Criteria of 21 CFR 1271.10(a)

A vendor stating that their facility is "FDA registered" does not automatically mean every product in their catalog qualifies as a compliant Section 361 allograft. Practice managers must review product inserts and manufacturing summaries against the four cumulative criteria of 21 CFR 1271.10(a).

1. Minimal Manipulation

The processing of the tissue must not alter its original relevant characteristics. The FDA separates tissues into two categories for this assessment:

• Structural tissue: Processing must not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. For example, decellularizing, lyophilizing, or cutting amniotic membrane to serve as a wound covering is generally considered minimal manipulation, whereas grinding or enzymatically digesting structural tissue into a fluid often crosses the threshold into more than minimal manipulation.
• Cellular or nonstructural tissue: Processing must not alter the relevant biological characteristics of cells or tissues (such as cord blood or bone marrow aspirate).

2. Homologous Use Only

The product must be intended to perform the same basic function or functions in the recipient as in the donor—specifically as reflected by the manufacturer's labeling, advertising, and objective intent. For instance, using an amniotic membrane externally as a barrier or cover aligns with its native structural role, whereas marketing a structural membrane for systemic metabolic rejuvenation does not.

3. No Prohibited Combinations

The manufacture of the HCT/P must not involve the combination of the cells or tissues with another article, with strict exceptions for water, crystalloids, or sterilizing, preserving, or storage agents—provided that these agents do not raise new clinical safety concerns.

4. No Systemic Effect or Dependence on Living Cells' Metabolic Activity

The HCT/P must not have a systemic effect and must not be dependent upon the metabolic activity of living cells for its primary function. The only statutory exceptions to this fourth criterion are products intended for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.

Step-by-Step Vendor Vetting and Verification Checklist

Before onboarding a new tissue bank or distributor, practice administrators should execute a standardized compliance audit. Use the following checklist to document your due diligence for every allograft SKU entering your facility:

• Verify Active FDA HCTERS Registration: Look up the source tissue establishment directly in the FDA's public Human Cell and Tissue Establishment Registration database. Confirm that their registration status is "Active" and that the specific tissue types they are selling are checked on their registration profile.
• Confirm AATB Accreditation: Verify whether the source tissue bank holds current accreditation from the American Association of Tissue Banks (AATB). While voluntary, AATB accreditation indicates adherence to rigorous donor screening, recovery, and processing standards that often exceed federal baselines.
• Review State-Specific Licensing: Confirm that both the tissue manufacturer and the distributor hold any required state-level tissue bank or medical device distribution licenses (such as state health department registrations in California, New York, Florida, or Texas).
• Audit Promotional Materials and Labeling: Examine the vendor's website, brochures, and package inserts. Ensure the language describes homologous, structural functions rather than making unapproved drug claims about curing specific diseases or systemic conditions.
• Check FDA Enforcement Databases: Search the FDA's public archives for Warning Letters, Untitled Letters, or Form 483 inspectional observations issued to the manufacturer. If a letter exists, require written documentation showing how the company remediated the findings and closed out the inquiry.
• Request a Sample Certificate of Analysis (CoA): Review how the lab documents donor eligibility (under 21 CFR Part 1271 Subpart C), infectious disease testing panels, sterility testing (such as USP <71>), and endotoxin limits.
• Inspect the FDA Tissue Reference Group (TRG) Correspondence: If a manufacturer claims they have verified their 361 status with the FDA, ask to review the formal response letter from the FDA's Tissue Reference Group or Office of Combination Products (OCP), noting that TRG letters apply strictly to the specific processing method and intended use submitted.

Clinical Considerations for Physicians and Medical Directors

While practice managers handle procurement, contract vetting, and record-keeping, the treating physician retains ultimate clinical and medical-legal responsibility for what is administered to a patient. For physicians in orthopedics, pain management, and aesthetics, regulatory compliance intersects directly with clinical practice in two ways: the "practice of medicine" exemption and informed consent.

First, clinicians should understand that while the FDA does not regulate the "practice of medicine" (allowing physicians discretion in how they use legally marketed products), this discretion does not shield a manufacturer or distributor who introduces an unapproved Section 351 biologic into interstate commerce. If a product is illegally marketed at the source due to more-than-minimal manipulation, the clinic's procurement channel is vulnerable to disruption or recall, and malpractice carriers may scrutinize the use of non-compliant biologics.

Second, medical directors must ensure that clinical documentation, informed consent forms, and patient-facing clinic marketing accurately reflect the regulatory status of the allograft. Consent forms should clearly state the nature of the human tissue allograft, its structural or homologous role, and that Section 361 HCT/Ps are regulated for communicable disease prevention rather than evaluated by the FDA for clinical efficacy via premarket trials.

Operationalizing Traceability and Cold-Chain Compliance

Verification does not end once a vendor is approved. Under 21 CFR 1271.290, tissue establishments must maintain tracking systems that enable the tracking of all HCT/Ps from the donor to the consignee (the clinic) and vice versa.

At the clinic level, practice managers must enforce strict intake and tissue log protocols:

1. Receiving Inspection: Staff must verify that cryopreserved or refrigerated biologics arrive within the manufacturer's validated temperature window, with intact tamper-evident seals and sufficient dry ice or phase-change packs.
2. Lot Number Tracking: Every allograft vial or membrane must have its unique donor identification code and lot number recorded in both a centralized clinic tissue log and the individual patient's electronic health record (EHR).
3. Tissue Return Cards: Complete and return the manufacturer's tissue utilization or implant record promptly after administration to close the traceability loop.
4. Adverse Event Reporting: Train clinical staff on the protocol for reporting any suspected communicable disease transmission or adverse reaction back to the source tissue bank and the FDA MedWatch system.

What This Means for Your Practice

Building a compliant regenerative service line requires treating vendor qualification with the same rigor as clinical protocol development. To protect your practice and streamline operations, take these immediate next steps:

• Audit your current inventory: Pull the package inserts and manufacturer details for all human tissue allografts currently in your clinic and verify their status in the FDA HCTERS database.
• Standardize your vendor onboarding: Require all prospective biologic sales representatives to submit their source lab's FDA registration number, AATB certificate, and sample CoA before scheduling a clinical presentation with your physicians.
• Consolidate through vetted distributors: Partnering with an established, licensed medical distributor reduces administrative friction by placing an additional layer of compliance vetting between your clinic and the manufacturing labs.

If your practice is evaluating regenerative biologics or looking to audit and consolidate your current supply chain, contact Dallas Regenerative Solutions to schedule an operational consultation with our team.